Pediatric Hematology Oncology | Specialty

Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma

December 23rd 2020

December 23, 2020 — Findings from the International, Prospective ALCL-Relapse trial showed that allogeneic SCT after reinduction chemotherapy can lead to survival improvements in children and adolescents with high-risk relapsed or refractory anaplastic large cell lymphoma, provide more insight into how to treat this population.

Pelvic, Abdominal Radiation in Pediatric Patients May Lead to Impaired Metabolic Health as Adults

December 3rd 2020

The use of abdominal or pelvic radiotherapy in pediatric patients with cancer could lead to long-term negative impact on cardiovascular and metabolic health.

Pediatric Osteosarcoma Harbors a High Incidence of Pathogenic TP53 Variants

October 19th 2020

TP53 was found to be the only gene with a germline de novo pathogenic or likely pathogenic variant in pediatric patients with osteosarcoma.

FDA Grants Nivatrotamab Orphan Drug Status for Pediatric Neuroblastoma

October 8th 2020

The FDA has granted an orphan drug designation and rare pediatric disease designation to the bispecific antibody nivatrotamab for the treatment of patients with neuroblastoma.

Experts Call for Increased Awareness of Existing Racial Disparities in RCC, Other Malignancies

September 24th 2020

Despite the numerous reports detailing racial differences in cancer outcomes and care over the years, the reasons underlying these disparities continue to be under deep exploration.

FDA Panel Supports Remestemcel-L for Pediatric Steroid-Refractory Acute GVHD

August 13th 2020

The FDA’s Oncologic Drugs Advisory Committee voted 8 to 2 in favor of approving remestemcel-L for the treatment of children with steroid-refractory acute graft-versus-host disease.

Stronger Racial and Ethnic Minority Presence Is Needed in Clinical Cancer Trials

August 12th 2020

Numerous analyses conducted over the past few years have underscored a serious issue in clinical cancer trials that needs to be addressed: a lack of racial and ethnic diversity among participants.

FDA Issues Complete Response Letter for Pedmark for Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

August 11th 2020

The FDA has issued a complete response letter to Fennec Pharmaceuticals regarding its new drug application for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.

FDA Grants Pedmark Priority Review for Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

August 7th 2020

The FDA has granted a priority review designation to a new drug application for a unique formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity in patients from 1 month to less than 18 years of age with localized, nonmetastatic, solid tumors.

FDA Approval Sought for Omburtamab in Pediatric Metastatic Neuroblastoma

August 6th 2020

The biologics license application for the investigational B7-H3–targeting monoclonal antibody omburtamab for use in pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma has been submitted to the FDA under the agency’s Rolling Review process.